Published in final edited form as:

Endocrinol Metab Clin North Am. 2009 December ; 38(4): 719–738. doi:10.1016/j.ecl.2009.08.004.

Etiology and Treatment of Hypogonadism in Adolescents

Vidhya Viswanathan, MD* and **Erica A. Eugster, MD**

Section of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Room 5960, 702 Barnhill Drive, Indianapolis, IN 46202, USA

Keywords

Hypergonadotropic hypogonadism; Hypogonadotropic hypogonadism; Adolescents; Delayed puberty; Treatment

Factors that mitigate the onset of puberty have yet to be fully elucidated. Gonadarche refers to the onset of gonadal sex steroid production during puberty. Gonadarche results from pulsatile gonadotropin releasing hormone (GnRH) secretion from the hypothalamus. GnRH secretion occurs every 60 to 90 minutes,¹ and there is subsequent release of the pituitary gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH) initially during sleep,² which leads to gonadal stimulation. LH stimulates Leydig cell hyperplasia in males and subsequent testosterone release. FSH has little effect in males until the onset of spermatogenesis (sperm maturation). In females, FSH stimulates the production of estradiol via ovarian follicular development. Testosterone and estradiol secretion lead to the development of secondary sexual characteristics. Adequate functioning at all levels of the hypothalamic-pituitary-gonadal axis is necessary for normal gonadal development and subsequent sex steroid production. Deficiencies at any level of the axis can lead to a hypogonadal state.

In boys, hypogonadism can manifest as a complete lack of secondary sexual development or failure of normal pubertal progression. In girls, it can present with failure of pubertal initiation, failure of pubertal progression, or menstrual irregularities. Abnormalities within the hypothalamus or pituitary lead to *hypogonadotropic hypogonadism* whereas primary gonadal failure is characterized as *hypergonadotropic hypogonadism*.

HYPOGONADOTROPIC HYPOGONADISM

Hypogonadotropic hypogonadism can be attributed to a variety of congenital origins including single gene mutations, idiopathic forms, and genetic syndromes. Acquired causes of hypogonadotropic hypogonadism include central nervous system (CNS) insults such as trauma, irradiation, and intracranial tumors. By far the most common cause of hypogonadotropic hypogonadism is transient, and is termed constitutional delay of growth and puberty (CDGP). Each of these causes is briefly discussed here, and the molecular genetic causes of hypogonadotropic hypogonadism are shown in Table 1.

*Corresponding author. vviswana@iupui.edu..

Constitutional Delay of Growth and Puberty

CDGP is a variation of normal development that can be difficult to differentiate from pathologic hypogonadotropic hypogonadism. In this condition, puberty and the pubertal growth spurt occur at or later than the extreme upper end of the normal age. The diagnosis is made more often in boys than girls, likely due to referral bias, and has a strongly familial pattern.³ Skeletal maturation is delayed in comparison with chronologic age. CDGP results in delayed but *normal* puberty; thus puberty progresses through the normal stages but starts at a later time. Children with CDGP achieve their genetic potential for height,⁴ and laboratory evaluation is normal. Some patients benefit from short-term treatment to augment secondary sexual development and boost linear growth.⁵

Congenital Origins

Gene defects

Nuclear receptor mutations: Nuclear receptors influence gene transcription at multiple levels, and exert their effects in a time- and dosage-specific fashion. An important nuclear receptor involved in gonadotropin secretion is steroidogenic factor-1 (SF-1), a key regulator of genes involved in sexual differentiation, steroidogenesis, and reproduction. SF-1 knockout mice show marked abnormalities in the development of the hypothalamus and impaired development of pituitary gonadotropes, with decreased levels of serum gonadotropins as well as gonadal dysgenesis.⁶ Target genes of SF-1 within the hypothalamus and pituitary include the gonadotropin releasing hormone receptor (GnRHR) and the β subunit of LH. Both heterozygous and homozygous mutations in the DNA binding domain of SF-1 result in complete XY sex reversal, testicular dysgenesis, and adrenal failure in genotypic males. A milder phenotype has also been described in which there is impaired gonadal but intact adrenal function.⁷ In a genetic female, a heterozygous SF-1 mutation has been associated with primary adrenal failure but normal ovarian development.⁸ Thus, SF-1 mutations exist within a broad clinical spectrum that will undoubtedly continue to expand.

DAX-1 is an orphan nuclear receptor that is involved in steroidogenesis and functions as a repressor of SF-1 mediated transcription. Mutations have been identified in *NROB1*, the gene that encodes DAX1, on the Xp21 locus. Males with DAX1 mutations typically present with early-onset adrenal insufficiency and subsequent delayed puberty secondary to hypogonadotropic hypogonadism.⁹ However, a delayed presentation of primary adrenal insufficiency has also been reported.¹⁰ DAX1 mutations can lead to both hypothalamic and pituitary dysfunction with decreased GnRH and gonadotropin secretion.¹¹ DAX1 mutations can also cause defects in spermatogenesis, and in one study affected males also had evidence of azospermia.¹² Therefore, mutations in DAX-1, as in SF-1, can lead to the development of hypogonadism in a multitude of ways.

Kallman syndrome: Impairment of GnRH secretion can also occur from defects in migration of GnRH producing neurons. Kallman syndrome (KS) refers to the combination of hypogonadotropic hypogonadism and anosmia. The X-linked form results from a defect in the migration of GnRH and olfactory neurons due to a mutation in the *KALI* gene. This gene encodes for anosmin-1, a glycoprotein essential for neuronal migration and growth.¹³ Individuals with KS also have aplasia of the olfactory bulb as noted on magnetic resonance

imaging (MRI).¹⁴ Although *KALI* gene defects have been the prototype of KS, there is emerging evidence that autosomal forms may be more prevalent than previously thought. In one study, *KALI* gene defects accounted for only 14% of cases with familial KS. Mutations in unidentified autosomal genes were postulated to cause the remainder. Subjects with presumed autosomal gene defects had some response to GnRH pulses, indicating partial preservation of hypothalamic GnRH-secreting neurons, though still with phenotypic similarity to the X-linked version of the syndrome.¹⁵ Fibroblast growth receptor 1 (FGFR1) mutations may account for as many as 10% of cases,¹⁶ and mutations in the prokineticin 2 (PROK2) gene have also been identified in individuals with KS and normosmic hypogonadotropic hypogonadism.¹⁷ No matter what the underlying molecular genetic cause, lack of adequate GnRH secretion leads to decreased circulating gonadotropins in both autosomal and X-linked cases.

Isolated hypogonadotropic hypogonadism: Isolated hypogonadotropic hypogonadism (IHH) refers to cases in which anosmia is absent. One potential cause is loss of function mutations of the GnRHR, a G-protein coupled receptor. At least 8 mutations of the GnRHR in 7 families have been identified. Notable genotype-phenotype variation exists even within members of the same kindred due to incomplete activation of GnRHR function.¹⁸ Males with these mutations display signs of hypogonadism and small testes. Females typically present with primary amenorrhea.¹⁹ Another important cause of IHH has been traced to mutations in GPR54, which has a critical role in hypothalamic GnRH signaling and release.²⁰ Of note, both KS and IHH may be found in the same kindred. IHH has also been noted to be reversible in some patients.²¹

Transcription factor mutations: Even with intact GnRH production and signal transduction, pituitary gonadotropin synthesis may still be deficient due to mutations in a variety of transcription factors. An important transcription factor involved in the developmental cascade of pituitary gonadotrope cells is Prop-1. Prop-1 is the product of the pituitary transcription factor Pit 1, a paired-like homeodomain transcription factor that is responsible for early embryonic pituitary development. Prop-1 gene mutations can result in familial combined pituitary hormone deficiency including growth hormone deficiency, central hypothyroidism, and hypogonadotropic hypogonadism.²² In one analysis of 8 members of a consanguineous family with Prop-1 gene mutations, all 8 family members had gonadotropin deficiency and failure of spontaneous sexual maturation.²³ There is also a variable pattern of phenotypic expressivity associated with Prop-1 mutations, with different deficiencies appearing at different time periods within the same family.

Like Prop-1, the transcription factor HESX1 is needed for normal pituitary development.²⁴ Deficiencies in HESX1, initially identified in 1998, are a rare cause of septo-optic dysplasia²⁵ which may be associated with hypogonadotropic hypogonadism.²⁶ Other transcription factors implicated in rare cases of hypogonadotropic hypogonadism include LHX4²⁷ and SOX 2.²⁸ All patients with hypopituitarism, including idiopathic forms, are at risk for hypogonadotropic hypogonadism.

Leptin and leptin receptor defects: Congenital leptin deficiency results from loss of function mutations of the *LEP* gene, which encodes for the leptin protein. Leptin interacts

with the leptin receptor, a member of the interleukin-6 family of receptors. This interaction stimulates the Jak-Stat pathway and leads to activation of downstream target genes. Leptin deficiency acts as a sign of nutritional deprivation and results in the suppression of the reproductive axis. Classic findings in individuals with leptin deficiency include hyperphagia, obesity, and hypogonadotropic hypogonadism. Administration of leptin seemingly rectifies these abnormalities.²⁹ Leptin receptor (LEPR) abnormalities have a similar phenotype to congenital leptin deficiency. Females with this mutation have hypogonadotropic hypogonadism. These girls present with delayed puberty, lack of a pubertal growth spurt, and reduced expression of secondary sexual characteristics. Some may have irregular menses due to aromatization of subcutaneous fat to estrogen, which then stimulates uterine hyperplasia. Males with leptin receptor mutations have hypogonadotropic hypogonadism and diminished testosterone production.³⁰

Syndromes—Numerous syndromes include neuroendocrine dysfunction as a potential feature. Perhaps the best known is Prader-Willi syndrome (PWS), which is caused by a genetic defect involving paternal chromosome 15, usually in the form of a microdeletion within the long arm or maternal unipaternal disomy.³¹ Hypothalamic dysfunction is marked in these patients as evidenced by their hypotonia, hyperphagia, and intermittent temperature instability. The hypothalamic dysfunction also leads to hypogonadism and may be attributed to an absence of or abnormal location of GnRH neurons. Early studies in individuals with PWS revealed low circulating serum gonadotropins and in males, attenuated testosterone response to human chorionic gonadotropin.³² Physical findings in boys include micropenis, scrotal hypoplasia, cryptorchidism, and small testes. Either absent or delayed puberty may ensue. In girls, findings may be less remarkable and include hypoplasia of the clitoris or labia minora, primary amenorrhea, and delayed puberty.³³ However, a wide spectrum of hypogonadism exists in PWS, with some women achieving fertility without hormone replacement therapy.^{34,35}

Acquired Origins

Any significant CNS insult can result in acquired hypogonadotropic hypogonadism. Two of the most common causes in children are traumatic brain injury and CNS tumors.

Traumatic brain injury—Traumatic brain injury (TBI) is an insult to the brain that results in neurologic dysfunction. TBI can have significant neurocognitive, neuropsychological, and neuroendocrine sequelae.^{36,37} Anterior pituitary insufficiency resulting from TBI has been noted in the past, but is garnering more attention as a high prevalence of pituitary hormone insufficiency has been demonstrated.³⁸ Some retrospective studies indicate that gonadotropin deficiency may be found in 90% to 95% of those with history of TBI,³⁹ although prospective studies in adults have noted the prevalence to be far less. In one study, hormonal evaluation was conducted on TBI patients at baseline (acute phase) and at 12 months. In the acute phase, approximately 42% of those evaluated had gonadotropin deficiency. At the 12-month follow-up, many of these patients spontaneously recovered reproductive function. The final prevalence of hypogonadism was 7.7%.⁴⁰ It is clear that all patients with a history of TBI require ongoing surveillance for pituitary problems, including hypogonadotropic hypogonadism.

Central nervous system tumors—Intracranial injury can also occur as a result of CNS tumors. In children, resultant hypogonadotropic hypogonadism can exist as a result of the primary tumor or due to the therapeutic regimen needed to treat the lesion. In a prospective study of 75 children with various CNS tumors, 13% had an abnormality in gonadotropin secretion before initiation of therapy.⁴¹ In a retrospective study focusing on craniopharyngioma, only 1 out of 64 patients had evidence of hypogonadism before treatment. However, after surgical resection and adjuvant radiotherapy, 80% of those evaluated at a pubertal age had evidence of hypogonadism.⁴² Gonadotropin deficiency and delayed puberty are most likely in those who receive 40 Gy or more of radiation.⁴³ Gonadotropin deficiency may continue to evolve for many years after irradiation, with rates of total incidence ranging from 20% to 50%.^{44,45} Therefore, all children who have CNS lesions should be monitored for gonadotropin deficiency and signs of pubertal delay.⁴⁶

Hypothalamic amenorrhea—Hypothalamic amenorrhea is commonly associated with eating disorders such as anorexia nervosa, and also occurs in elite female athletes. Clinical manifestations include absence of menstrual cycles, increased exercise, and weight loss. In these girls, suppression of GnRH secretion results in attenuation of LH and FSH release, and decreased estrogen production.⁴⁷ Several theories have been postulated for this hypothalamic dysfunction, including low circulating energy levels due to high energy expenditure and relative deficiency of nutritional intake.⁴⁷ Girls with hypothalamic amenorrhea also have low circulating leptin levels. Administration of recombinant leptin to some women with hypothalamic amenorrhea leads to elevated LH and estradiol, resulting in follicular growth and ovulation.⁴⁸

HYPERGONADOTROPIC HYPOGONADISM

Primary hypogonadism can be due to congenital origins such as chromosomal abnormalities, syndromes, or genetic mutations. Primary hypogonadism can also be acquired later in childhood or adolescence due to autoimmunity or exposure to chemotherapy or radiation. Alterations in gonadotropins, the gonadotropin receptors, or within the gonads themselves can lead to hypogonadism with decreased testosterone and estradiol secretion. The decreased sex steroid secretion causes increased production of gonadotropins manifesting as hypergonadotropic hypogonadism. Congenital causes of primary hypogonadism are outlined in Table 2.

Congenital Origins

The most common cause of congenital primary hypogonadism is sex chromosome aneuploidy as is present in Turner syndrome and Klinefelter syndrome. Isolated abnormalities of the X chromosome are also associated with primary ovarian failure.

Turner syndrome—Turner syndrome (TS) occurs in 1 in 2500 live born females.⁴⁹ Diagnosis of the syndrome requires the combination of characteristic physical features, including short stature as well as partial or complete absence of an X chromosome.⁵⁰ More than half of girls with TS have chromosomal mosaicism. Approximately 30% will begin puberty spontaneously, but only a small minority will progress to menarche.⁵¹ Spontaneous pregnancy has been reported but is extremely rare in this population.⁵² Although initially

intrinsically normal, the ovaries in girls with TS undergo accelerated atresia such that ovarian failure is often already present and may be detected at birth. Precisely which genes on the X chromosome are necessary for ovarian maintenance is unknown. FSH levels during early life have been found to be significantly lower in girls with mosaic TS as compared with those who are monosomic.⁵³

Klinefelter syndrome—Klinefelter syndrome is the most common congenital cause of primary hypogonadism and occurs in 1 in 1000 live male births.⁵⁴ The most common genotype is XXY, although variants exist with different numbers of X chromosomes. Tall stature, a eunuchoid body habitus, gynecomastia, and small, firm testes are cardinal features. Seminiferous tubule dysgenesis is a classic histologic feature of the testes. Individuals with Klinefelter syndrome exhibit a spectrum of gonadal failure, with many men going undiagnosed until they present with infertility in adulthood. However, a significant number come to attention during adolescence due to delayed puberty or lack of appropriate pubertal progression.

X chromosome abnormalities—Other X chromosome abnormalities, including Xq deletion and Triple X, can cause varying degrees of hypogonadism. Xq deletion can cause a phenotype similar to TS as well as isolated premature ovarian failure.⁵⁵ Deletions in the critical region, Xq13-q26, can also lead to premature ovarian failure.⁵⁶ Triple X, 47 XXX, is estimated to exist in 1 in 1000 girls and is marked by significant phenotypic variability.⁵⁷ Women with this condition can be tall and have normal external genitalia, with preservation of ovarian function.⁵⁷ These women can also have ovarian failure as well as significant genitourinary tract anomalies, including cloacal exstrophy and müllerian abnormalities.^{58,59}

Abnormalities in gonadotropin production or action—Mutations within the β subunit of the gonadotropins, the gonadotropin receptors, or forms of resistance to gonadotropins can all result in hypergonadotropic hypogonadism. Females with mutations in the β subunit of FSH present with primary amenorrhea, delayed puberty, and poorly developed secondary sexual characteristics; they have low FSH levels, low estradiol levels, and high LH levels due to lack of feedback inhibition by estradiol.^{60,61} Males with the same mutation have normal to delayed puberty and azospermia.⁶²

A homozygous mutation within the LH β subunit has resulted in total functional loss in one male.⁶³ The individual in this case presented with delayed puberty, low serum testosterone, and high LH levels. It was discovered later that several male members in his family were infertile. In further studies, it was noted that females with this defect present with ovarian dysfunction, infertility, menstrual irregularity, or polycystic ovary syndrome.⁶⁴

Inactivating mutations of the G-protein coupled FSH and LH receptors result in a phenotype similar to those with abnormalities in the LH and FSH β subunits. Complete LH resistance results from a loss of function mutation in the LH receptor gene. In males, this causes a phenotype that ranges from micropenis, to ambiguous genitalia, to completely female external genitalia.^{65,66} In females, LH resistance results in normal puberty but subsequent amenorrhea, infertility, and elevated LH levels, demonstrating that ovulation requires LH as well as FSH.⁶⁷ FSH resistance due to FSH receptor mutations has also been reported,

particularly in the Finnish population. Women who are homozygous for this defect have gonadal dysgenesis and primary amenorrhea.⁶⁸ In contrast, men from the same kindreds have variable degrees of infertility.

A rare congenital condition associated with gonadotropin resistance is carbohydrate-deficient glycoprotein syndrome, which causes defects in gonadotropin glycosylation. In females with this defect, FSH seems to have less bioactivity and leads to decreased serum estradiol levels. However, exogenous FSH results in an increase in estradiol. Males with this disease advance through puberty but have decreased testicular volume.⁶⁹

Resistance syndromes can also be due to variations in the signal transduction pathway after gonadotropin binding. Pseudohypoparathyroidism is a disease in which the signal transduction pathway of many hormones is altered due to inactivating mutations of the $G_s \alpha$ subunit. The mutation leads to multiple hormone resistance. In a study of 12 patients with pseudohypoparathyroidism, 25% of the pubertal patients had evidence of gonadotropin resistance.⁷⁰

Disorders of sex development—Disorders of sex development (DSDs) are congenital conditions in which development of chromosomal, gonadal, or anatomic sex is atypical.⁷¹ This broad category includes common entities such as TS and Klinefelter Syndrome, as well as rare disorders such as cloacal exstrophy, mixed gonadal dysgenesis, and congenital aphallia. Many DSDs are associated with ambiguous genitalia, which is beyond the scope of this review. However, a few may present with delayed puberty or primary amenorrhea, and are important to consider in the differential diagnosis of an adolescent with apparent hypogonadism. These DSDs include Swyer syndrome, complete androgen insensitivity syndrome (CAIS), and rare forms of congenital adrenal hyperplasia (CAH), all of which result in female external genitalia.

Swyer syndrome: Swyer syndrome, also known as XY pure gonadal dysgenesis, is characterized by tall stature, primary amenorrhea, and delayed puberty in a phenotypic female. Laboratory studies reveal elevated gonadotropins, and ultrasonographic examination reveals bilateral streak gonads and a hypoplastic uterus.⁷² Fifteen to thirty percent of these individuals have mutations in SRY (sex-determining region of the Y chromosome) or alterations in the Y chromosome.⁷³ There is also a high risk of gonadal tumors such as dysgerminoma or gonadoblastoma.⁷³ Therefore, gonadectomy is routinely recommended when this diagnosis is made.

Complete androgen insensitivity syndrome: CAIS is caused by mutations of the androgen receptor that result in loss of testosterone and dihydrotestosterone mediated action. Androgen receptor mutations are X-linked recessive in 70% of cases, and are found in 1 in 20,000 to 1 in 90,000 genetic males.⁷⁴ The most common phenotype is that of an adolescent girl who has normal breast development, but absent or scant body hair and primary amenorrhea. Examination of the external genitalia reveals a normal female phenotype with a blind ending vagina. Eighty percent to 90% of girls with CAIS will also eventually develop inguinal hernias,⁷⁵ with some presenting in infancy with this diagnosis.

Congenital adrenal hyperplasia: Rare forms of CAH can present with hypogonadism due to lack of production of testosterone and estrogen. These conditions include deficiencies of 17 α -hydroxylase, side chain cleavage enzyme (SCC), and steroid acute regulatory protein (StAR). Girls with 17 α -hydroxylase deficiency can present with primary amenorrhea and absent secondary sexual characteristics. Boys have female external genitalia, a blind vagina, and intra-abdominal testes.⁷⁶ Hypertension and hypokalemia may also be present.⁷⁷ SCC is the first step in the steroidogenic pathway and converts cholesterol to pregnenolone. SCC deficiency leads to deficiencies in all steroid hormones. SCC deficiency in genetic males leads to XY sex reversal and adrenal insufficiency.⁷⁸ StAR, a protein expressed in the adrenal cortex and gonads, increases cholesterol transport in response to steroidogenic stimuli. Affected genetic males present in early infancy with adrenal crisis, and appear phenotypically female.⁷⁹ Affected genetic females are normally developed at birth and may have intact ovarian function.⁸⁰

Galactosemia: Another congenital cause of primary hypogonadism is galactosemia. Galactosemia results from a deficiency in galactose-1-phosphate uridylyltransferase (GALT) and presents with clinical manifestations of cataracts, *Escherichia coli* sepsis, poor growth, and feeding dysfunction if undiagnosed in the newborn. In an initial study conducted in 1981, gonadal function was evaluated in 12 women and 8 men with galactosemia. Although gonadal function was normal in men with the disease, the women in this study had evidence of hypergonadotropic hypogonadism, with varying degrees of primary and secondary amenorrhea and oligomenorrhea.⁸¹ Ultrasound studies of the ovaries in those affected demonstrated streak gonads in several women.⁸¹ The cause of the hypogonadism is most likely premature ovarian failure, although the exact pathophysiology is not well understood. Numerous theories exist, including the hypothesis that galactose-1-phosphate is toxic and perhaps competitively inhibits UDP-Galactose transferase and alters FSH and FSH receptors, with subsequent failure of ovarian follicles to develop.⁸² This process manifests as an elevated FSH in 85% of girls younger than 10 years who have galactosemia and premature ovarian failure.⁸²

Testicular regression sequence: Testicular regression sequence (TRS), or vanishing testis syndrome, occurs when an initially normal testicle that existed in fetal life subsequently atrophies. Most individuals with TRS have normal male external genitalia, reflecting that normal testicular function existed during prenatal life. The most likely cause of this syndrome is fetal or antenatal testicular torsion, or trauma to scrotal contents in utero.⁸³ This view is supported by the finding of hemosiderin laden macrophages and dystrophic calcifications under histopathologic examination.⁸⁴ There has also been an association noted between testicular regression and persistence of mullerian duct structures.⁸⁵ Thus far, a search for a molecular genetic cause of TRS has been negative.⁸⁶

Acquired Origins

The acquired forms of primary hypogonadism are as varied as the congenital forms. Important acquired origins include treatment for pediatric cancer (radiation and chemotherapy) and autoimmune conditions.

Chemotherapy and radiation—Both chemotherapy and radiation have been noted to cause primary hypogonadism. In girls, the dose of intra-abdominal radiation needed to destroy more than 50% of developing oocytes is less than 2 Gy.⁸⁷ In the 70% of patients who survive pediatric cancer, 1 in 6 female survivors develops primary ovarian failure. Those who do undergo spontaneous menarche have decreased ovarian reserve.⁸⁸ In boys, depressed spermatogenesis can be seen after a testicular radiation dose as low as 0.15 Gy, with temporary azoospermia occurring after doses of 0.3 Gy.⁸⁹ The effect of radiation on testicular function is age dependent, with prepubertal radiation exposure causing significantly more damage to Leydig cells than postpubertal radiation.⁹⁰ Cumulative doses of alkylating agents are also correlated with altered function.⁸⁹

A high prevalence of hypogonadism was noted in young adult survivors of childhood cancer who participated in a study comparing 3 treatment arms for non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The study compared treatment with chemotherapy alone (vincristine, prednisolone, l-asparaginase, methotrexate, 6-mercaptopurine), combined chemotherapy and prophylactic cranial radiation, and chemotherapy with total body radiation and bone marrow transplant. All women in the third category had premature ovarian failure. Women in the other 2 categories, however, had intact ovarian function. Among men in the third category, 83% had primary hypogonadism, with a low serum testosterone and elevated FSH and LH. Forty percent of men in all 3 treatment arms had alterations in spermatogenesis, with the greatest dysfunction appearing in those who had received total body radiation.⁹¹

Despite these findings, there have been reports of spontaneous recovery of testicular or ovarian function in childhood cancer survivors. Although more common in older children and adults, recovery of ovarian function has occurred as long as 12 years post exposure to radiation and alkylating chemotherapy in a young girl.⁹² Due to the increased risk of gonadal dysfunction in pediatric cancer patients and also due to the chance of spontaneous recovery, recommendations for surveillance include yearly monitoring of pubertal status with Tanner staging and assessment of growth velocity. Laboratory measurements of FSH and LH as well as estradiol or testosterone are recommended for those with signs of pubertal delay.⁹³

Autoimmune gonadal failure—Autoimmunity can lead to both testicular and ovarian failure, specifically in those who have other types of autoimmune endocrinopathies. Several autoimmune polyglandular syndromes (APS) have been identified. Of these, APS I and APS II have been associated with premature ovarian failure at prevalence rates of 30% to 50%.⁹⁴ APS I consists of a triad of hypoparathyroidism, mucocutaneous candidiasis, and adrenal insufficiency. The mutation is within the *AIRE* gene, the autoimmune regulator. In a Finnish cohort, approximately 50% of the females identified with APS I had premature ovarian failure. Two-thirds of these individuals had autoantibodies to side-chain cleavage enzyme (anti-SCC),⁹⁵ one of the enzymes identified in steroid production that is specific to the ovary and is noted in autoimmune ovarian failure. In those who have been diagnosed with APS I and who initially have signs of ovarian failure, the presence of steroid cell antibodies may signal progression of the disease process.⁹⁶ APS II consists of autoimmune adrenocortical failure along with thyroid disease or diabetes. Positive antibodies to the P450 enzymes,

specifically ovary-specific antibodies, in the steroid production pathway are thought to mediate autoimmune ovarian failure in this syndrome as well.⁹⁷ Autoimmunity can also cause isolated premature ovarian failure,⁹⁸ and has also been reported in conditions such as systemic lupus erythematosus and myasthenia gravis.

Testicular failure occurs at a lower rate than ovarian failure in APS.⁹⁹ Autoimmunity to the Leydig cells in APS may be mediated by P450 autoantibodies that are testis specific.¹⁰⁰ Antisperm antibodies have also been noted in prepubertal boys treated with chemotherapy and in those with urogenital tract abnormalities such as cryptorchidism, testicular torsion, or hypospadias.¹⁰¹

EVALUATION

Evaluation of a child with delayed puberty begins with a careful history and physical examination. Important elements on history include the parents' pubertal timing, because late menarche in the mother or delayed completion of adult height in the father is strongly suggestive of CDGP. Eliciting a family history of hypogonadism, autoimmune syndromes, DSDs, or consanguinity is also essential. History in the child should include attention to any CNS insult or symptoms of chronic disease. In the review of systems, lack of sense of smell can be an important clue to the presence of KS.

Physical examination should include height and weight measurements. Neurologic assessment should include evaluation of visual fields. Assessment of secondary sexual characteristics includes Tanner staging and recognition of evidence of androgen exposure. Testicular enlargement, which can sometimes go unnoticed by boys, indicates the onset of central puberty. Stigmata of TS or Klinefelter Syndrome should be noted. The external genitalia should be visually inspected for any signs of anatomic abnormality.

Laboratory evaluation including plasma gonadotropin levels, estradiol, or testosterone may be helpful. Low gonadotropin levels suggest CDGP or pathologic hypogonadotropic hypogonadism, and can be further evaluated with a GnRH stimulation test.¹⁰² In contrast, elevated gonadotropins indicate primary gonadal failure. A bone age radiograph is an essential component of the evaluation. Other tests that may be indicated, depending on the individual situation, include a head MRI, karyotype, auto-immune panel, or molecular genetic analysis. In patients with suspected CDGP, a "wait and see" approach is typically employed to determine whether spontaneous puberty will ensue.

TREATMENT

Although there are many causes of hypogonadism in children, the treatment is primarily focused on hormone replacement with sex steroids. The overarching goal is to simulate a normal progression of pubertal development that also allows for the attainment of genetic potential for height.

Estrogen Replacement

Estrogen therapy is initially started for pubertal induction and breast development in girls with hypogonadism. Studies regarding estrogen therapy in children have focused primarily

on girls with TS. Recommended starting doses of estrogen therapy in this population are one-eighth to one-tenth the doses used for adult replacement, and vary depending on the formulation used. Very low doses have been reported to have a salutary effect on linear growth in TS.¹⁰³ Multiple different formulations of estrogen are available, and include oral estradiol, oral conjugated estrogen, trans-dermal estrogen patches, and estrogen gel. The age at which estrogen therapy is initiated is individualized and incorporates factors such as chronologic age, bone age, absolute height, and psychosocial issues. The starting dose is low and is gradually increased over several years. Equivalent adult doses of oral therapy are micronized estradiol, 2 mg, esterified estrogen, 1.25 mg, ethinyl estradiol, 8 to 10 µg, and conjugated estrogens, 1.25 mg.¹⁰⁴ Addition of progesterone 1 week per month, usually in the form of medroxyprogesterone, after 1 to 2 years of estrogen therapy or post breakthrough bleeding, allows for adequate breast and uterine development. Formulations and available doses of estrogen preparations are shown in Table 3.

Limitations of oral estrogen therapy include variable bioavailability due to first-pass metabolism within the liver, which subsequently affects liver function and clotting factors.^{105,106} As a result, transdermal estrogen formulations are gaining in popularity. Estrogen patches are widely used in adult women, and doses of 0.625 and 1.25 mg of oral conjugated estrogens have been reported to be similar those of 50 and 100 µg of transdermal estradiol per 24 hours.¹⁰⁷ Pubertal induction can be accomplished with transdermal estradiol at a dose as low as 3.1 to 6.2 µg/24 hours.¹⁰⁶ Puberty can then be mimicked with subsequent doubling of the dose after a median duration of 8 months and addition of progesterone 2 years after estrogen initiation. A transdermal estrogen dose of 0.1 mg/d is equivalent to an adult regimen. When comparing transdermal estrogen to oral estrogen, significantly higher levels of 17β-estradiol were noted with oral estrogen. However, no differences in metabolic effects including lipolysis, lipid, and carbohydrate oxidation, and resting energy expenditure from short-term transdermal versus oral estrogen therapy have been noted.¹⁰⁵ In contrast, a pilot study of transdermal versus oral conjugated estrogen in girls with TS found better bone mineral accrual and uterine development in the transdermal group.¹⁰⁸ Percutaneous estradiol gel has also been investigated for pubertal induction in girls with TS at a starting dose of 0.1 mg nightly with increases of 0.1 mg for each additional year up to 5 years. Side effects of percutaneous gel therapy include local skin irritation, and this modality is not currently in use in the clinical setting.¹⁰⁹ For hypogonadal women, estrogen replacement is needed throughout reproductive life.

Testosterone Replacement

In boys, studies involving testosterone for pubertal induction have primarily focused on CDGP and KS. Testosterone therapy is usually initiated at 15% to 25% of adult doses. Approximately 50 to 100 mg of a testosterone ester formulation is given intra-muscularly every 2 to 4 weeks for 4 to 6 months with gradual increases to adult doses.^{110,111} In boys with CDGP, a 4- to 6-month course of 50 to 100 mg testosterone per month may be offered to bring about initial secondary sexual characteristics and boost linear growth.¹¹⁰ In boys who have permanent hypogonadism, the need for therapy is lifelong. Even at the initial doses used for pubertal induction, there is a decrease in total fat mass, percent body fat, and whole body proteolysis once testosterone is initiated.¹¹²

Intramuscular, transdermal, and oral formulations of testosterone exist. The preparations testosterone enanthate and testosterone cypionate are the most often used formulations in children, due to the difficulty in delivering the small doses needed initially for pubertal induction with alternate forms.¹¹³ Intramuscular injections of testosterone, however, can be painful for the adolescent patient population, and studies investigating other formulations are ongoing.

Formal guidelines regarding the use of oral preparations have yet to be delineated, and experience with this form of testosterone is far less than with the intramuscular form. Transdermal testosterone, in the form of testosterone gel, at doses of 50 mg/m²/d has been used in children short-term to treat poor growth secondary to renal failure.¹¹⁴ In a study of transdermal testosterone delivered via a 5-mg patch, overnight use in boys with delayed puberty resulted in pubertal testosterone concentrations as well short-term growth.¹¹⁵ Side effects of transdermal testosterone include local skin irritation. As in oral testosterone therapy, there are limited studies regarding the use of transdermal preparations of testosterone, and intramuscular testosterone therapy remains the mainstay of therapy for pediatric patients. Testosterone preparations and adult doses are shown in Table 4.

Adjunctive treatment in the form of human chorionic gonadotropin has been suggested in boys with PWS in whom beneficial effects on body composition and endogenous testosterone secretion have been observed.¹¹⁶

SUMMARY

In conclusion, causes of hypogonadism are heterogeneous and may involve any level of the reproductive system. Whereas some conditions are clearly delineated, the exact etiology and underlying pathogenesis of many disorders is unknown. Regardless of the form of hypogonadism, the crux of therapy in children revolves around sex steroid replacement. Continued molecular genetic investigation and prospective clinical trials will enhance knowledge and improve management of hypogonadism in pediatric patients.

References

1. Boyar R, Finkelstein J, Roffwarg H, et al. Synchronization of augmented luteinizing hormone secretion with sleep during puberty. *N Engl J Med*. 1972; 287(12):582–6. [PubMed: 4341276]. [PubMed: 4341276]
2. Apter D, Butzow TL, Laughlin GA, et al. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins. *J Clin Endocrinol Metab*. 1993; 76(4):940–9. [PubMed: 8473410]. [PubMed: 8473410]
3. Sedlmeyer IL, Palmert MR. Delayed puberty: analysis of a large case series from an academic center. *J Clin Endocrinol Metab*. 2002; 87(4):1613–20. [PubMed: 11932291]. [PubMed: 11932291]
4. von Kalckreuth G, Haverkamp F, Kessler M, et al. Constitutional delay of growth and puberty: do they really reach their target height? *Horm Res*. 1991; 35(6):222–5. [PubMed: 1819545]. [PubMed: 1819545]
5. Bergada I, Bergada C. Long term treatment with low dose testosterone in constitutional delay of growth and puberty: effect on bone age maturation and pubertal progression. *J Pediatr Endocrinol Metab*. 1995; 8(2):117–22. [PubMed: 7584705]. [PubMed: 7584705]
6. Achermann JC, Weiss J, Lee EJ, et al. Inherited disorders of the gonadotropin hormones. *Mol Cell Endocrinol*. 2001; 179(1–2):89–96. [PubMed: 11420133]. [PubMed: 11420133]

7. Kohler B, Lin L, Ferraz-de-Souza B, et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46, XY patients with severe underandrogenization but without adrenal insufficiency. *Hum Mutat.* 2008; 29(1):59–64. [PubMed: 17694559]. [PubMed: 17694559]
8. Biason-Lauber A, Schoenle EJ. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. *Am J Hum Genet.* 2000; 67(6):1563–8. [PubMed: 11038323]. [PubMed: 11038323]
9. Muscatelli F, Strom TM, Walker AP, et al. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. *Nature.* 1994; 372(6507):672–6. [PubMed: 7990958]. [PubMed: 7990958]
10. Yang F, Hanaki K, Kinoshita T, et al. Late-onset adrenal hypoplasia congenita caused by a novel mutation of the DAX-1 gene. *Eur J Pediatr.* 2009; 168:329–31. [PubMed: 18607630]. [PubMed: 18607630]
11. Habiby RL, Boepple P, Nachtigall L, et al. Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalamic and pituitary defects in gonadotropin production. *J Clin Invest.* 1996; 98(4):1055–62. [PubMed: 8770879]. [PubMed: 8770879]
12. Mantovani G, De Menis E, Borretta G, et al. DAX1 and X-linked adrenal hypoplasia congenita: clinical and molecular analysis in five patients. *Eur J Endocrinol.* 2006; 154(5):685–9. [PubMed: 16645015]. [PubMed: 16645015]
13. Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. *Nature.* 1991; 353(6344):529–36. [PubMed: 1922361]. [PubMed: 1922361]
14. Vogl TJ, Stemmler J, Heye B, et al. Kallman syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging. *Radiology.* 1994; 191(1):53–7. [PubMed: 8134597]. [PubMed: 8134597]
15. Oliveira LM, Seminara SB, Beranova M, et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. *J Clin Endocrinol Metab.* 2001; 86(4):1532–8. [PubMed: 11297579]. [PubMed: 11297579]
16. Sato N, Katsumata N, Kagami M, et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. *J Clin Endocrinol Metab.* 2004; 89(3):1079–88. [PubMed: 15001591]. [PubMed: 15001591]
17. Pitteloud N, Zhang C, Pignatelli D, et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci U S A.* 2007; 104(44):17447–52. [PubMed: 17959774]. [PubMed: 17959774]
18. de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. *N Engl J Med.* 1997; 337(22):1597–602. [PubMed: 9371856]. [PubMed: 9371856]
19. de Roux N, Milgrom E. Inherited disorders of GnRH and gonadotropin receptors. *Mol Cell Endocrinol.* 2001; 179(1–2):83–7. [PubMed: 11420132]. [PubMed: 11420132]
20. de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. *Proc Natl Acad Sci U S A.* 2003; 100(19):10972–6. [PubMed: 12944565]. [PubMed: 12944565]
21. Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. *N Engl J Med.* 2007; 357(9):863–73. [PubMed: 17761590]. [PubMed: 17761590]
22. Pfaffle RW, Blankenstein O, Wuller S, et al. Combined pituitary hormone deficiency: role of Pit-1 and Prop-1. *Acta Paediatr Suppl.* 1999; 88(433):33–41. [PubMed: 10626543]. [PubMed: 10626543]
23. Lazar L, Gat-Yablonski G, Kornreich L, et al. PROP-1 gene mutation (R120C) causing combined pituitary hormone deficiencies with variable clinical course in eight siblings of one Jewish Moroccan family. *Horm Res.* 2003; 60(5):227–31. [PubMed: 14614227]. [PubMed: 14614227]
24. Dasen JS, Barbera JP, Herman TS, et al. Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. *Genes Dev.* 2001; 15(23):3193–207. [PubMed: 11731482]. [PubMed: 11731482]

25. Dattani MT, Martinez-Barbera JP, Thomas PQ, et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septooptic dysplasia in human and mouse. *Nat Genet.* 1998; 19(2):125–33. [PubMed: 9620767]. [PubMed: 9620767]
26. Haddad NG, Eugster EA. Hypopituitarism and neurodevelopmental abnormalities in relation to central nervous system structural defects in children with optic nerve hypoplasia. *J Pediatr Endocrinol Metab.* 2005; 18(9):853–8. [PubMed: 16279362]. [PubMed: 16279362]
27. Pfaeffle RW, Hunter CS, Savage JJ, et al. Three novel missense mutations within the LHX4 gene are associated with variable pituitary hormone deficiencies. *J Clin Endocrinol Metab.* 2008; 93(3):1062–71. [PubMed: 18073311]. [PubMed: 18073311]
28. Kelberman D, Rizzoti K, Avilion A, et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. *J Clin Invest.* 2006; 116(9):2442–55. [PubMed: 16932809]. [PubMed: 16932809]
29. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, Tcell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. *J Clin Invest.* 2002; 110(8):1093–103. [PubMed: 12393845]. [PubMed: 12393845]
30. Farooqi IS, Wangenstein T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. *N Engl J Med.* 2007; 356(3):237–47. [PubMed: 17229951]. [PubMed: 17229951]
31. Wharton RH, Loechner KJ. Genetic and clinical advances in Prader-Willi syndrome. *Curr Opin Pediatr.* 1996; 8(6):618–24. [PubMed: 9018447]. [PubMed: 9018447]
32. Jeffcoate WJ, Laurance BM, Edwards CR, et al. Endocrine function in the Prader-Willi syndrome. *Clin Endocrinol (Oxf).* 1980; 12(1):81–9. [PubMed: 6769611]. [PubMed: 6769611]
33. Crino A, Schiaffini R, Ciampalini P, et al. Hypogonadism and pubertal development in Prader-Willi syndrome. *Eur J Pediatr.* 2003; 162(5):327–33. [PubMed: 12692714]. [PubMed: 12692714]
34. Schulze A, Mogensen H, Hamborg-Petersen B, et al. Fertility in Prader-Willi syndrome: a case report with Angelman syndrome in the offspring. *Acta Paediatr.* 2001; 90(4):455–9. [PubMed: 11332942]. [PubMed: 11332942]
35. Akefeldt A, Tornhage CJ, Gillberg C. A woman with Prader-Willi syndrome gives birth to a healthy baby girl. *Dev Med Child Neurol.* 1999; 41(11):789–90. [PubMed: 10576646]. [PubMed: 10576646]
36. Morton MV, Wehman P. Psychosocial and emotional sequelae of individuals with traumatic brain injury: a literature review and recommendations. *Brain Inj.* 1995; 9(1):81–92. [PubMed: 7874099]. [PubMed: 7874099]
37. Kelly DF, Gonzalo IT, Cohan P, et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. *J Neurosurg.* 2000; 93(5):743–52. [PubMed: 11059653]. [PubMed: 11059653]
38. Lieberman SA, Oberoi AL, Gilkison CR, et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. *J Clin Endocrinol Metab.* 2001; 86(6):2752–6. [PubMed: 11397882]. [PubMed: 11397882]
39. Benvenga S, Campenni A, Ruggeri RM, et al. Clinical review 113: hypopituitarism secondary to head trauma. *J Clin Endocrinol Metab.* 2000; 85(4):1353–61. [PubMed: 10770165]. [PubMed: 10770165]
40. Tanriverdi F, Senyurek H, Unluhizarci K, et al. High risk of hypopituitarism after traumatic brain injury: a prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma. *J Clin Endocrinol Metab.* 2006; 91(6):2105–11. [PubMed: 16522687]. [PubMed: 16522687]
41. Merchant TE, Williams T, Smith JM, et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. *Int J Radiat Oncol Biol Phys.* 2002; 54(1):45–50. [PubMed: 12182973]. [PubMed: 12182973]
42. Gonc EN, Yordam N, Ozon A, et al. Endocrinological outcome of different treatment options in children with craniopharyngioma: a retrospective analysis of 66 cases. *Pediatr Neurosurg.* 2004; 40(3):112–9. [PubMed: 15367800]. [PubMed: 15367800]

43. Mills JL, Fears TR, Robison LL, et al. Menarche in a cohort of 188 long-term survivors of acute lymphoblastic leukemia. *J Pediatr*. 1997; 131(4):598–602. [PubMed: 9386666]. [PubMed: 9386666]
44. Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. *N Engl J Med*. 1993; 328(2):87–94. [PubMed: 8416438]. [PubMed: 8416438]
45. Rappaport R, Brauner R, Czernichow P, et al. Effect of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. *J Clin Endocrinol Metab*. 1982; 54(6):1164–8. [PubMed: 6804477]. [PubMed: 6804477]
46. Nandagopal R, Laverdiere C, Mulrooney D, et al. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. *Horm Res*. 2008; 69(2):65–74. [PubMed: 18059086]. [PubMed: 18059086]
47. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. *Lancet*. 2005; 366(9479):74–85. [PubMed: 15993236]. [PubMed: 15993236]
48. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. *N Engl J Med*. 2004; 351(10):987–97. [PubMed: 15342807]. [PubMed: 15342807]
49. Nielsen J, Wohler M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. *Hum Genet*. 1991; 87(1):81–3. [PubMed: 2037286]. [PubMed: 2037286]
50. Bondy CA. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. *J Clin Endocrinol Metab*. 2007; 92(1):10–25. [PubMed: 17047017]. [PubMed: 17047017]
51. Pasquino AM, Passeri F, Pucarelli I, et al. Italian Study Group for Turner's Syndrome. Spontaneous pubertal development in Turner's syndrome. *J Clin Endocrinol Metab*. 1997; 82(6):1810–3. [PubMed: 9177387]. [PubMed: 9177387]
52. Hovatta O. Pregnancies in women with Turner's syndrome. *Ann Med*. 1999; 31(2):106–10. [PubMed: 10344582]. [PubMed: 10344582]
53. Fechner PY, Davenport ML, Qualy RL, et al. Differences in follicle-stimulating hormone secretion between 45, X monosomy Turner syndrome and 45, X/46, XX mosaicism are evident at an early age. *J Clin Endocrinol Metab*. 2006; 91(12):4896–902. [PubMed: 16968797]. [PubMed: 16968797]
54. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. *J Clin Endocrinol Metab*. 2003; 88(2):622–6. [PubMed: 12574191]. [PubMed: 12574191]
55. Abulhasan SJ, Tayel SM, al-Awadi SA. Mosaic Turner syndrome: cytogenetics versus FISH. *Ann Hum Genet*. 1999; 63(Pt 3):199–206. [PubMed: 10738532]. [PubMed: 10738532]
56. Rizzolio F, Bione S, Sala C, et al. Chromosomal rearrangements in Xq and premature ovarian failure: mapping of 25 new cases and review of the literature. *Hum Reprod*. 2006; 21(6):1477–83. [PubMed: 16497693]. [PubMed: 16497693]
57. Linden MG, Bender BG, Harmon RJ, et al. 47, XXX: what is the prognosis? *Pediatrics*. 1988; 82(4):619–30. [PubMed: 2459656]. [PubMed: 2459656]
58. Lin HJ, Ndiforhu F, Patell S. Exstrophy of the cloaca in a 47, XXX child: review of genitourinary malformations in triple-X patients. *Am J Med Genet*. 1993; 45(6):761–3. [PubMed: 8456857]. [PubMed: 8456857]
59. Holland CM. 47, XXX in an adolescent with premature ovarian failure and auto-immune disease. *J Pediatr Adolesc Gynecol*. 2001; 14(2):77–80. [PubMed: 11479104]. [PubMed: 11479104]
60. Matthews CH, Borgato S, Beck-Peccoz P, et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. *Nat Genet*. 1993; 5(1):83–6. [PubMed: 8220432]. [PubMed: 8220432]
61. Layman LC, Lee EJ, Peak DB, et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. *N Engl J Med*. 1997; 337(9):607–11. [PubMed: 9271483]. [PubMed: 9271483]
62. Lindstedt G, Nystrom E, Matthews C, et al. Follitropin (FSH) deficiency in an infertile male due to FSHbeta gene mutation. A syndrome of normal puberty and virilization but underdeveloped

- testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. *Clin Chem Lab Med*. 1998; 36(8):663–5. [PubMed: 9806482]. [PubMed: 9806482]
63. Weiss J, Axelrod L, Whitcomb RW, et al. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. *N Engl J Med*. 1992; 326(3):179–83. [PubMed: 1727547]. [PubMed: 1727547]
 64. Furui K, Suganuma N, Tsukahara S, et al. Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants. *J Clin Endocrinol Metab*. 1994; 78(1):107–13. [PubMed: 7904610]. [PubMed: 7904610]
 65. Kremer H, Kraaij R, Toledo SP, et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. *Nat Genet*. 1995; 9(2):160–4. [PubMed: 7719343]. [PubMed: 7719343]
 66. Latronico AC, Anasti J, Arnhold JJ, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. *N Engl J Med*. 1996; 334(8):507–12. [PubMed: 8559204]. [PubMed: 8559204]
 67. Arnhold JJ, Latronico AC, Batista MC, et al. Clinical features of women with resistance to luteinizing hormone. *Clin Endocrinol (Oxf)*. 1999; 51(6):701–7. [PubMed: 10619974]. [PubMed: 10619974]
 68. Aittomaki K. The genetics of XX gonadal dysgenesis. *Am J Hum Genet*. 1994; 54(5):844–51. [PubMed: 8178824]. [PubMed: 8178824]
 69. de Zegher F, Jaeken J. Endocrinology of the carbohydrate-deficient glycoprotein syndrome type 1 from birth through adolescence. *Pediatr Res*. 1995; 37(4 Pt 1):395–401. [PubMed: 7596677]. [PubMed: 7596677]
 70. Gelfand IM, Eugster EA, DiMeglio LA. Presentation and clinical progression of pseudohypoparathyroidism with multi-hormone resistance and Albright hereditary osteodystrophy: a case series. *J Pediatr*. 2006; 149(6):877–80. [PubMed: 17137912]. [PubMed: 17137912]
 71. Lee PA, Houk CP, Ahmed SF, et al. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex Pediatrics. 2006; 118(2):e488–500. [PubMed: 16882788]
 72. Michala L, Goswami D, Creighton SM, et al. Swyer syndrome: presentation and outcomes. *BJOG*. May; 2008 115(6):737–41. [PubMed: 18410658]. [PubMed: 18410658]
 73. Zielinska D, Zajacsek S, Rzepka-Gorska I. Tumors of dysgenetic gonads in Swyer syndrome. *J Pediatr Surg*. 2007; 42(10):1721–4. [PubMed: 17923202]. [PubMed: 17923202]
 74. Oakes MB, Eyvazzadeh AD, Quint E, et al. Complete androgen insensitivity syndrome—a review. *J Pediatr Adolesc Gynecol*. 2008; 21(6):305–10. [PubMed: 19064222]. [PubMed: 19064222]
 75. Sarpel U, Palmer SK, Dolgin SE. The incidence of complete androgen insensitivity in girls with inguinal hernias and assessment of screening by vaginal length measurement. *J Pediatr Surg*. 2005; 40(1):133–6. discussion: 136–7. [PubMed: 15868573]. [PubMed: 15868573]
 76. Costa-Santos M, Kater CE, Auchus RJ. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. *J Clin Endocrinol Metab*. 2004; 89(1):49–60. [PubMed: 14715827]. [PubMed: 14715827]
 77. Yang J, Cui B, Sun S, et al. Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene. *J Clin Endocrinol Metab*. 2006; 91(9):3619–25. [PubMed: 16772352]. [PubMed: 16772352]
 78. al Kandari H, Katsumata N, Alexander S, et al. Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46, XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. *J Clin Endocrinol Metab*. 2006; 91(8):2821–6. [PubMed: 16705068]. [PubMed: 16705068]
 79. Baker BY, Lin L, Kim CJ, et al. Nonclassic congenital lipid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. *J Clin Endocrinol Metab*. 2006; 91(12):4781–5. [PubMed: 16968793]. [PubMed: 16968793]
 80. Fujieda K, Tajima T, Nakae J, et al. Spontaneous puberty in 46, XX subjects with congenital lipid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating

- mutations in the steroidogenic acute regulatory protein (StAR) gene. *J Clin Invest*. 1997; 99(6): 1265–71. [PubMed: 9077535]. [PubMed: 9077535]
81. Kaufman FR, Kogut MD, Donnell GN, et al. Hypergonadotropic hypogonadism in female patients with galactosemia. *N Engl J Med*. 1981; 304(17):994–8. [PubMed: 6782485]. [PubMed: 6782485]
82. Prestoz LL, Couto AS, Shin YS, et al. Altered follicle stimulating hormone isoforms in female galactosaemia patients. *Eur J Pediatr*. 1997; 156(2):116–20. [PubMed: 9039515]. [PubMed: 9039515]
83. Smith NM, Byard RW, Bourne AJ. Testicular regression syndrome—a pathological study of 77 cases. *Histopathology*. 1991; 19(3):269–72. [PubMed: 1916702]. [PubMed: 1916702]
84. Law H, Mushtaq I, Wingrove K, et al. Histopathological features of testicular regression syndrome: relation to patient age and implications for management. *Fetal Pediatr Pathol*. 2006; 25(2):119–29. [PubMed: 16908461]. [PubMed: 16908461]
85. Imbeaud S, Rey R, Berta P, et al. Testicular degeneration in three patients with the persistent mullerian duct syndrome. *Eur J Pediatr*. 1995; 154(3):187–90. [PubMed: 7758514]. [PubMed: 7758514]
86. Vinci G, Anjot MN, Trivin C, et al. An analysis of the genetic factors involved in testicular descent in a cohort of 14 male patients with anorchia. *J Clin Endocrinol Metab*. 2004; 89(12):6282–5. [PubMed: 15579790]. [PubMed: 15579790]
87. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. *Hum Reprod*. 2003; 18(1):117–21. [PubMed: 12525451]. [PubMed: 12525451]
88. Larsen EC, Muller J, Schmiegelow K, et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. *J Clin Endocrinol Metab*. 2003; 88(11): 5307–14. [PubMed: 14602766]. [PubMed: 14602766]
89. Lopez Andreu JA, Fernandez PJ, Ferris i Tortajada J, et al. Persistent altered spermatogenesis in long-term childhood cancer survivors. *Pediatr Hematol Oncol*. 2000; 17(1):21–30. [PubMed: 10689712]. [PubMed: 10689712]
90. Shalet SM, Tsatsoulis A, Whitehead E, et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. *J Endocrinol*. 1989; 120(1):161–5. [PubMed: 2493061]. [PubMed: 2493061]
91. Steffens M, Beauloye V, Brichard B, et al. Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). *Clin Endocrinol (Oxf)*. 2008; 69(5):819–27. [PubMed: 18429947]. [PubMed: 18429947]
92. Rahhal SN, Eugster EA. Unexpected recovery of ovarian function many years after bone marrow transplantation. *J Pediatr*. 2008; 152(2):289–90. [PubMed: 18206705]. [PubMed: 18206705]
93. Meacham LR, Ghim TT, Crocker IR, et al. Systematic approach for detection of endocrine disorders in children treated for brain tumors. *Med Pediatr Oncol*. 1997; 29(2):86–91. [PubMed: 9180908]. [PubMed: 9180908]
94. Schatz DA, Winter WE. Autoimmune polyglandular syndrome. II: clinical syndrome and treatment. *Endocrinol Metab Clin North Am*. 2002; 31(2):339–52. [PubMed: 12092454]. [PubMed: 12092454]
95. Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. *J Clin Endocrinol Metab*. 2007; 92(2):595–603. [PubMed: 17118990]. [PubMed: 17118990]
96. Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. *J Clin Endocrinol Metab*. 1987; 64(3):494–500. [PubMed: 3818889]. [PubMed: 3818889]
97. Uiho R, Aavik E, Peterson P, et al. Autoantibodies to cytochrome P450 enzymes P450_{scc}, P450_{c17}, and P450_{c21} in autoimmune polyglandular disease types I and II and in isolated Addison's disease. *J Clin Endocrinol Metab*. 1994; 78(2):323–8. [PubMed: 8106620]. [PubMed: 8106620]
98. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. *Endocr Rev*. 1997; 18(1):107–34. [PubMed: 9034788]. [PubMed: 9034788]

99. Buzi F, Badolato R, Mazza C, et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time to review diagnostic criteria? *J Clin Endocrinol Metab.* 2003; 88(7): 3146–8. [PubMed: 12843157]. [PubMed: 12843157]
100. Perniola R, Falorni A, Clemente MG, et al. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). *Eur J Endocrinol.* 2000; 143(4):497–503. [PubMed: 11022196]. [PubMed: 11022196]
101. Sinisi AA, D'Apuzzo A, Pasquali D, et al. Antisperm antibodies in prepubertal boys treated with chemotherapy for malignant or non-malignant diseases and in boys with genital tract abnormalities. *Int J Androl.* 1997; 20(1):23–8. [PubMed: 9202987]. [PubMed: 9202987]
102. Goodpasture JC, Ghai K, Cara JF, et al. Potential of gonadotropin-releasing hormone agonists in the diagnosis of pubertal disorders in girls. *Clin Obstet Gynecol.* 1993; 36(3):773–85. [PubMed: 8403624]. [PubMed: 8403624]
103. Rosenfield RL, Perovic N, Devine N, et al. Optimizing estrogen replacement treatment in Turner syndrome. *Pediatrics.* 1998; 102(2 Pt 3):486–8. [PubMed: 9685449]. [PubMed: 9685449]
104. Donaldson MD, Gault EJ, Tan KW, et al. Optimising management in Turner syndrome: from infancy to adult transfer. *Arch Dis Child.* 2006; 91(6):513–20. [PubMed: 16714725]. [PubMed: 16714725]
105. Mauras N, Shulman D, Hsiang HY, et al. Metabolic effects of oral versus trans-dermal estrogen in growth hormone-treated girls with turner syndrome. *J Clin Endocrinol Metab.* 2007; 92(11): 4154–60. [PubMed: 17711924]. [PubMed: 17711924]
106. Ankarberg-Lindgren C, Elfving M, Wikland KA, et al. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. *J Clin Endocrinol Metab.* 2001; 86(7):3039–44. [PubMed: 11443165]. [PubMed: 11443165]
107. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. *N Engl J Med.* 1986; 314(25):1615–20. [PubMed: 3012339]. [PubMed: 3012339]
108. Nabhan ZM, DiMeglio LA, Qi R, et al. Oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. *J Clin Endocrinol Metab.* 2009; 94(6):2009–14. [PubMed: 19318455]. [PubMed: 19318455]
109. Piippo S, Lenko H, Kainulainen P, et al. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. *J Clin Endocrinol Metab.* 2004; 89(7):3241–7. [PubMed: 15240598]. [PubMed: 15240598]
110. Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. *N Engl J Med.* 1988; 319(24):1563–7. [PubMed: 3200264]. [PubMed: 3200264]
111. Soliman AT, Khadir MM, Asfour M. Testosterone treatment in adolescent boys with constitutional delay of growth and development. *Metabolism.* 1995; 44(8):1013–5. [PubMed: 7637642]. [PubMed: 7637642]
112. Arslanian S, Suprasongsin C. Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism. *J Clin Endocrinol Metab.* 1997; 82(10):3213–20. [PubMed: 9329341]. [PubMed: 9329341]
113. Rogol AD. Pubertal androgen therapy in boys. *Pediatr Endocrinol Rev.* 2005; 2(3):383–90. [PubMed: 16429115]. [PubMed: 16429115]
114. Kassmann K, Rappaport R, Broyer M. The short-term effect of testosterone on growth in boys on hemodialysis. *Clin Nephrol.* 1992; 37(3):148–54. [PubMed: 1563120]. [PubMed: 1563120]
115. Mayo A, Macintyre H, Wallace AM, et al. Transdermal testosterone application: pharmacokinetics and effects on pubertal status, short-term growth, and bone turnover. *J Clin Endocrinol Metab.* 2004; 89(2):681–7. [PubMed: 14764781]. [PubMed: 14764781]
116. Eiholzer U, Grieser J, Schlumpf M, et al. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. *Horm Res.* 2007; 68(4):178–84. [PubMed: 17374959]. [PubMed: 17374959]

Table 1

Molecular genetic causes of hypogonadotropic hypogonadism

Gene	Product	Inheritance	Target Sites	Additional Clinical Manifestations
<i>SF-1</i>	Orphan nuclear receptor	Autosomal recessive	Steroidogenesis in males Hypothalamus Pituitary Adrenals	XY sex reversal, adrenal failure In females: adrenal failure, normal ovarian function
<i>DAX-1</i>	Orphan nuclear receptor	X-linked recessive	Steroidogenesis Hypothalamus Pituitary Adrenals	In males: spectrum of hypogonadotropic hypogonadism and adrenal insufficiency
<i>KAL-1</i>	Anosmin	X-linked recessive	Hypothalamic neuronal migration	Anosmia
<i>FGFR1</i>	FGF receptor	Autosomal dominant	FGF receptor in hypothalamus Pituitary	Cleft palate Agenesis of corpus callosum
<i>GPR54</i>	G protein coupled receptor	Autosomal recessive	GnRH-secreting neurons Pituitary	Isolated hypogonadotropic hypogonadism
<i>Prop-1</i>	Transcription factor	Sporadic autosomal recessive	Pituitary gonadotrope development	Growth hormone deficiency Central hypothyroidism
<i>Hex-1</i>	Transcription factor	Sporadic	Prop-1 Pituitary gonadotrope development	Septo-optic dysplasia Central hypothyroidism Central hypocortisolism Diabetes insipidus
<i>LEP</i>	Leptin	Autosomal dominant	Hypothalamus	Obesity Hyperphagia T-cell immune dysfunction
<i>LEPR</i>	Leptin receptor	Autosomal dominant	Hypothalamus	Obesity Hyperphagia T-cell immune dysfunction

Table 2

Causes and clinical manifestations of congenital hypergonadotropic hypogonadism

Abnormality	Clinical Manifestations	
Turner syndrome	Short stature, webbed neck, cubitus valgus Streak ovaries	
Klinefelter syndrome	Tall stature Eunuchoid body habitus Small, firm testes	
X chromosome abnormality	Xq-premature ovarian failure XXX-tall stature GU abnormalities	
FSH and LH β subunit mutations	<i>Males</i>	<i>Females</i>
	Delayed puberty	Primary amenorrhea
	Azoospermia	Menstrual irregularity
	Infertility	Polycystic ovary syndrome
FSH and LH receptor mutations	<i>Males</i>	<i>Females</i>
	Micropenis	Primary amenorrhea
	Ambiguous genitalia	Gonadal dysgenesis
	XY sex reversal	
	Infertility	
Swyer syndrome (46, XY)	Tall stature Primary amenorrhea Delayed puberty Gonadal tumors	
CAIS (46, XY)	Primary amenorrhea Normal breast development Sparse body hair Absent mullerian and wolffian structures	
CAH (depending on deficiency)	Hypertension Hypokalemia XY sex reversal Adrenal crisis	
Galactosemia	Ovarian failure	
Testicular regression sequence	Normal external genitalia	

Table 3

Estrogen formulations

Type of Estrogen	Trade Name	Available Doses
Oral estradiol	Estrace	0.5, 1, 2 mg
	Gynodiol	0.5, 1, 2 mg
Oral esterified estrogen	Menest	0.3, 0.625, 1.25, 2.5 mg
	Ogen	Equivalent to 0.625 mg and above
	Ortho-Est	Equivalent to 0.625 mg and above
Oral conjugated equine estrogen	Premarin	0.3, 0.45, 0.625, 0.9, 1.25 mg
Estradiol patches	Vivelle	0.025, 0.0375, 0.05, 0.075, 0.1 mg/d
	Menostar	0.014 mg/d
Estradiol gel	Divigel	0.5 mg estradiol/5 g gel

Table 4

Testosterone formulations

Formulation	Trade Name	Dose (Adult)
IM testosterone enanthate	Delatestryl	250 mg every 2–4 wk
IM testosterone cypionate	Depo-Testosterone	250 mg every 2–4 wk
Oral testosterone undecanoate	Andriol (40 mg capsules)	2 capsules (2–3 times per day)
Testosterone patch	Androderm	5 mg/patch changed twice weekly
Testosterone gel	Androgel (25 mg testosterone/2.5 g gel) (50 mg testosterone/5 g gel)	50–100 mg/d
Buccal testosterone	Striant 30 mg tablet	1 tablet twice a day
Testosterone implants	Testopel 75 mg per pellet	3–4 pellets every 4–6 mo